Proton pump inhibitors and sensitization of cancer cells to radiation therapy.
cancer cells
molecular mechanisms
proton pump inhibitors
radiation resistance
radiosensitization
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
05
05
2022
accepted:
30
06
2022
entrez:
22
8
2022
pubmed:
23
8
2022
medline:
23
8
2022
Statut:
epublish
Résumé
This review article outlines six molecular pathways that confer resistance of cancer cells to ionizing radiation, and describes how proton pump inhibitors (PPIs) may be used to overcome radioresistance induced by alteration of one or more of these signaling pathways. The inflammatory, adaptive, hypoxia, DNA damage repair, cell adhesion, and developmental pathways have all been linked to the resistance of cancer cells to ionizing radiation. Here we describe the molecular link between alteration of these pathways in cancer cells and development of resistance to ionizing radiation, and discuss emerging data on the use of PPIs to favorably modify one or more components of these pathways to sensitize cancer cells to ionizing radiation. Understanding the relationship between altered signaling pathways, radioresistance, and biological activity of PPIs may serve as a basis to repurpose PPIs to restore key biological processes that are involved in cancer progression and to sensitize cancer cells to radiation therapy.
Identifiants
pubmed: 35992826
doi: 10.3389/fonc.2022.937166
pmc: PMC9388769
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
937166Subventions
Organisme : NHLBI NIH HHS
ID : K01 HL118683
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR077445
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL137703
Pays : United States
Organisme : NIAMS NIH HHS
ID : R56 AR077445
Pays : United States
Informations de copyright
Copyright © 2022 Hebert, Bonnen and Ghebre.
Déclaration de conflit d'intérêts
YG is an inventor on patents, owned by Stanford University and Baylor College of Medicine, that protect the use of proton pump inhibitors (PPIs) for therapeutic use of new indications. MDB is an inventor on the patent owned by Baylor College of Medicine. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest.
Références
Oncotarget. 2015 Oct 27;6(33):35040-50
pubmed: 26418900
Cancers (Basel). 2015 Aug 11;7(3):1554-85
pubmed: 26270676
Ann Oncol. 2020 Apr;31(4):525-531
pubmed: 32115349
Cancer Chemother Pharmacol. 2017 Nov;80(5):925-937
pubmed: 28861639
Oncogene. 2008 Dec 4;27(53):6738-48
pubmed: 18695676
Oncotarget. 2021 Jul 06;12(14):1339-1353
pubmed: 34262645
Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13012-7
pubmed: 9789032
Nat Genet. 2002 Mar;30(3):285-9
pubmed: 11836499
Biochem Biophys Res Commun. 1993 Oct 29;196(2):699-706
pubmed: 8240346
Cancer Treat Rev. 2012 Nov;38(7):904-10
pubmed: 22651903
Cancer Lett. 2009 Jul 18;280(1):110-9
pubmed: 19299075
Cancer Res. 2005 Oct 15;65(20):9501-9
pubmed: 16230415
Int J Mol Sci. 2020 May 29;21(11):
pubmed: 32485921
Oncologist. 2018 Jan;23(1):2-e5
pubmed: 29158365
J Clin Invest. 2007 Dec;117(12):3660-3
pubmed: 18060028
Int J Nanomedicine. 2018 Oct 04;13:6049-6058
pubmed: 30323592
J Exp Clin Cancer Res. 2010 May 08;29:44
pubmed: 20459683
J Cell Physiol. 2009 Oct;221(1):189-94
pubmed: 19492417
Front Oncol. 2019 Oct 10;9:1009
pubmed: 31649878
Cancer Lett. 2015 Jan 28;356(2 Pt B):697-703
pubmed: 25449440
Mediators Inflamm. 1997;6(3):185-93
pubmed: 18472819
J Bioenerg Biomembr. 2013 Oct;45(5):467-75
pubmed: 23813080
Nucleic Acids Res. 2003 Sep 1;31(17):4959-64
pubmed: 12930944
Br J Cancer. 2015 Mar 3;112(5):832-40
pubmed: 25647012
Oncol Rep. 2013 Aug;30(2):851-5
pubmed: 23754096
J Clin Invest. 2012 Apr;122(4):1529-40
pubmed: 22378044
Int J Radiat Biol. 2007 Nov-Dec;83(11-12):727-32
pubmed: 17952769
Cancer Treat Rev. 2019 Jun;76:41-50
pubmed: 31125907
Antioxid Redox Signal. 2002 Jun;4(3):491-9
pubmed: 12215217
Int J Oncol. 2012 Jan;40(1):170-5
pubmed: 21956158
Radiother Oncol. 2014 Apr;111(1):72-80
pubmed: 24631147
Cancer Res. 2005 Aug 1;65(15):6843-9
pubmed: 16061667
Am J Physiol Cell Physiol. 2004 Jun;286(6):C1443-52
pubmed: 14761893
Cell Mol Neurobiol. 2018 Nov;38(8):1491-1504
pubmed: 30302629
Mol Cell Biol. 2007 Aug;27(15):5597-605
pubmed: 17548475
Oncogene. 2001 Nov 29;20(55):7987-91
pubmed: 11753681
Radiat Res. 2019 Nov;192(5):473-482
pubmed: 31415221
Radiat Res. 2003 Jan;159(1):86-93
pubmed: 12492371
Lancet Oncol. 2008 Mar;9(3):288-96
pubmed: 18308254
Cell Cycle. 2010 Feb 1;9(3):472-8
pubmed: 20081365
Oncol Rep. 2018 Dec;40(6):3752-3762
pubmed: 30272295
Mol Cancer Ther. 2016 Jun;15(6):1177-89
pubmed: 26960983
Clin Sci (Lond). 2019 Feb 12;133(3):483-495
pubmed: 30705106
Aliment Pharmacol Ther. 2000 Apr;14 Suppl 1:74-81
pubmed: 10807407
Int J Mol Sci. 2013 Jul 16;14(7):14800-32
pubmed: 23863691
J Natl Cancer Inst. 2004 Nov 17;96(22):1702-13
pubmed: 15547183
Int J Radiat Biol. 2017 Apr;93(4):381-385
pubmed: 27910734
Oncotarget. 2016 Jul 5;7(27):41251-41264
pubmed: 27183910
Cancer Res. 2007 Jun 1;67(11):5408-17
pubmed: 17545622
Strahlenther Onkol. 2003 May;179(5):337-44
pubmed: 12740661
J Pharm Pharm Sci. 2014;17(3):439-46
pubmed: 25224353
Cancer Prev Res (Phila). 2010 Aug;3(8):963-74
pubmed: 20628001
Mol Cell Biol. 2003 Apr;23(7):2362-78
pubmed: 12640121
Int J Biochem Cell Biol. 2013 Dec;45(12):2736-48
pubmed: 24076216
Biomed Pharmacother. 2019 Dec;120:109478
pubmed: 31568987
Int J Radiat Biol. 1997 Aug;72(2):157-62
pubmed: 9269308
Front Biosci (Elite Ed). 2012 Jan 01;4(6):2142-9
pubmed: 22202026
Br J Cancer. 2012 Aug 7;107(4):652-7
pubmed: 22805327
Cancer Lett. 2016 Jul 1;376(2):278-83
pubmed: 27084522
Int Immunopharmacol. 2013 Nov;17(3):585-92
pubmed: 23973653
Inflamm Res. 2006 Nov;55(11):476-80
pubmed: 17122965
J Exp Clin Cancer Res. 2015 Aug 22;34:85
pubmed: 26297142
Nature. 2009 Apr 9;458(7239):776-9
pubmed: 19169242
Oral Oncol. 2004 Apr;40(4):383-9
pubmed: 14969817
Cancer. 2005 Sep 15;104(6):1129-37
pubmed: 16080176
Nat Rev Mol Cell Biol. 2002 Feb;3(2):94-103
pubmed: 11836511
Clin Cancer Res. 2020 Oct 15;26(20):5487-5493
pubmed: 32933995
Dev Cell. 2009 Sep;17(3):387-402
pubmed: 19758563
Int J Cancer. 2010 Jul 1;127(1):207-19
pubmed: 19876915
Lab Invest. 2012 Mar;92(3):466-73
pubmed: 22083670
J Cancer Res Clin Oncol. 2014 Jan;140(1):1-14
pubmed: 23990015
Biomed Res Int. 2017;2017:1832494
pubmed: 29226125
PLoS One. 2011;6(5):e20143
pubmed: 21629657
J Biol Chem. 2013 Mar 29;288(13):8875-86
pubmed: 23393139
Int J Cancer. 2001 Sep;93(6):869-74
pubmed: 11519050
Oncoimmunology. 2013 Jan 1;2(1):e22058
pubmed: 23483769
Cancer Res. 2014 Dec 1;74(23):7024-36
pubmed: 25297633
Cancer Prev Res (Phila). 2014 Dec;7(12):1258-69
pubmed: 25468899
J Transl Med. 2015 Aug 01;13:249
pubmed: 26231702
Cancer Lett. 2021 Jul 1;509:1-12
pubmed: 33813001
Oncotarget. 2016 Sep 27;7(39):63106-63123
pubmed: 27527858
Nat Rev Immunol. 2018 May;18(5):309-324
pubmed: 29379212
Curr Pharm Des. 2016;22(5):518-26
pubmed: 26601970
Onco Targets Ther. 2018 Oct 10;11:6705-6722
pubmed: 30349304
J Clin Biochem Nutr. 2009 Jul;45(1):86-92
pubmed: 19590712
Expert Rev Anticancer Ther. 2013 Oct;13(10):1229-42
pubmed: 24099530
Cancer Res. 2002 Feb 15;62(4):1213-21
pubmed: 11861406
Indian J Hematol Blood Transfus. 2017 Dec;33(4):500-508
pubmed: 29075060
Front Pharmacol. 2022 Mar 14;13:798272
pubmed: 35359844
Oncol Rep. 2016 Dec;36(6):3207-3214
pubmed: 27748935
Cancer Cell Int. 2013 Apr 16;13:36
pubmed: 23590596
BMC Cancer. 2018 Nov 12;18(1):1092
pubmed: 30419852
J Exp Clin Cancer Res. 2014 Sep 01;33:73
pubmed: 25175076
PLoS One. 2013;8(1):e54565
pubmed: 23382914
J Mol Med (Berl). 2016 Dec;94(12):1313-1326
pubmed: 27695879
J Cell Biol. 2011 Aug 8;194(3):367-75
pubmed: 21807880
Radiat Res. 2009 Jan;171(1):9-21
pubmed: 19138055
J Transl Med. 2013 Oct 24;11:268
pubmed: 24156349
Lab Invest. 2001 Mar;81(3):349-60
pubmed: 11310828
Genes Cancer. 2011 Dec;2(12):1117-33
pubmed: 22866203
Radiat Oncol. 2013 Jun 27;8:159
pubmed: 23806095
Clin Cancer Res. 1999 Aug;5(8):2069-76
pubmed: 10473088
Transl Oncol. 2019 Oct;12(10):1334-1344
pubmed: 31352196
Front Oncol. 2020 Jul 07;10:1120
pubmed: 32733808
J Natl Cancer Inst. 1999 Nov 17;91(22):1956-60
pubmed: 10564680
Front Oncol. 2020 Feb 20;10:164
pubmed: 32154167
Int J Med Sci. 2012;9(3):193-9
pubmed: 22408567
Nat Rev Cancer. 2009 Jun;9(6):400-14
pubmed: 19440234